A new genome-wide association study has identified 41 previously unknown loci associated with Alzheimer disease. However, these data provide limited insight into disease mechanisms or benefits for clinical prediction of Alzheimer disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
Genome Medicine Open Access 04 October 2023
-
Reply to: Genome-wide association studies of polygenic risk score-derived phenotypes may lead to inflated false positive rates
Scientific Reports Open Access 14 March 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bertram, L. & Tanzi, R. E. Genomic mechanisms in Alzheimer’s disease. Brain Pathol. 30, 966–977 (2020).
Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat. Genet. 51, 404–413 (2019).
Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat. Genet. 53, 1276–1282 (2021).
Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022).
Escott-Price, V. & Hardy, J. Genome wide association studies for Alzheimer’s disease: bigger is not always better. Brain Commun. https://doi.org/10.1093/braincomms/fcac125 (2022).
Griciuc, A. & Tanzi, R. E. The role of innate immune genes in Alzheimer’s disease. Curr. Opin. Neurol. 34, 228–236 (2021).
Kachuri, L. et al. Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction. Nat. Commun. 11, 6084 (2020).
Lambert, S. A., Abraham, G. & Inouye, M. Towards clinical utility of polygenic risk scores. Hum. Mol. Genet. 28, R133–R142 (2019).
Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50, 1219–1224 (2018).
Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 21, 66–77 (2022).
Acknowledgements
Both authors are supported by grants from the Deutsche Forschungsgemeinschaft (DFG), the European Research Council (ERC) and the Cure Alzheimer’s Fund (CAF). C.M.L. is also supported by the Michael J. Fox Foundation for Parkinson’s Research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Lill, C.M., Bertram, L. Genome-wide analysis furthers decoding of Alzheimer disease genetics. Nat Rev Neurol 18, 387–388 (2022). https://doi.org/10.1038/s41582-022-00678-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-022-00678-x
This article is cited by
-
Reply to: Genome-wide association studies of polygenic risk score-derived phenotypes may lead to inflated false positive rates
Scientific Reports (2023)
-
Comparative neurogenetics of dog behavior complements efforts towards human neuropsychiatric genetics
Human Genetics (2023)
-
Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
Genome Medicine (2023)